ANIK
Anika Therapeutics, Inc.
ANIK has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ANIK overall, supported by stronger fundamentals and stronger modeled upside.
ANIK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Stable | |
| Strong |
ANIK's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ANIK PE Valuation
ANIK has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ANIK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ANIK, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ANIK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.91 | — |
| Q3 2026 | -$0.13 | +$2.15 |
| Q2 2026 | -$0.27 | +$3.88 |
| Q1 2026 | -$0.79 | +$3.09 |
| Q4 2025 | -$0.76 | +$3.09 |
| Q3 2025 | -$2.28 | +$4.36 |
| Q2 2025 | -$4.15 | +$0.91 |
| Q1 2025 | -$3.88 | +$1.36 |
| Q4 2024 | -$3.85 | +$1.79 |
ANIK is still losing money, but far less than before: $0.13 per share over the past year, against $6.64 at its worst in late 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ANIK on earnings quality, reporting a profit while its opponent remains loss making.
ANIK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30.6M | +10% |
| Q2 2026 | $32.6M | +16% |
| Q1 2026 | $29.6M | +13% |
| Q3 2025 | $27.8M | -28% |
| Q2 2025 | $28.2M | -33% |
| Q1 2025 | $26.2M | -35% |
| Q3 2024 | $38.8M | -6.5% |
| Q2 2024 | $41.9M | -5.4% |
ANIK's revenue is recovering but still below its 2023 peak: $31M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.3% | -35 points |
| Q2 2026 | 9.1% | +24 points |
| Q1 2026 | -19% | -2.2 points |
| Q4 2025 | 2.1% | N/A |
| Q3 2025 | 32% | +105 points |
| Q2 2025 | -15% | -15 points |
| Q1 2025 | -16% | -3.9 points |
| Q3 2024 | -72% | -54 points |
ANIK's operating margin was −2.3% last quarter, down 35 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ANIK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ANIK on profitability, with a higher operating margin.
ANIK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.7M | +35% |
| Q2 2026 | -$2.1M | -$477K |
| Q1 2026 | -$6.3M | -$3.3M |
| Q4 2025 | $4M | +1351% |
| Q3 2025 | $5M | +31% |
| Q2 2025 | -$1.7M | +$2.8M |
| Q1 2025 | -$3M | -$1M |
| Q4 2024 | $275K | -85% |
ANIK still generates free cash flow, though less than at its 2019 peak: $2M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ANIK on cash flow, with more consistent year-over-year improvement.
ANIK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.4% | -329K shares |
| 1 year | -7.2% | -1M shares |
| 3 years | -8.5% | -1.2M shares |
| 5 years | -8.6% | -1.3M shares |
| Available history | -8.4% | -1.2M shares |
ANIK has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $853,000 |
| Q1 2026 | $8.7M |
| Q4 2025 | $5.5M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $4M |
| Q4 2024 | $5.6M |
ANIK spent $15M buying back its own shares over the past year, up 58% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ANIK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -14.7x | Net Cash |
| Q2 2026 | -3.0x | Net Cash |
| Q1 2026 | -7.6x | Net Cash |
| Q4 2025 | -8.8x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q1 2022 | -36.9x | Net Cash |
| Q4 2021 | -10.4x | Net Cash |
| Q3 2021 | -45.8x | Net Cash |
ANIK has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ANIK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 29.4 | Neutral |
ANIK's weekly RSI is 36 (neutral) and its Stochastic is 29 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ANIK PE vs Healthcare Sector
| Metric | ANIK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ANIK has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ANIK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.7 | 26% below |
| 20 week MA | $18.9 | 27% below |
| 50 week MA | $15.2 | 9% below |
| 100 week MA | $13.8 | 0.1% above |
| 200 week MA | $19.0 | 27% below |
ANIK's trend is mixed: it's above one of its five weekly moving averages, and 27% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ANIK on trend strength, trading above more of its moving averages.
ANIK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $52.8 | $43.2 | -18% |
| 2021 | $43.2 | $38.0 | -12% |
| 2022 | $38.0 | $27.9 | -27% |
| 2023 | $27.9 | $22.7 | -19% |
| 2024 | $22.7 | $16.2 | -28% |
| 2025 | $16.2 | $9.55 | -41% |
| 2026 YTD | $9.55 | $13.8 | +45% |
ANIK has finished every year since 2020 lower, and it's up 45% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ANIK on returns for 2026, with the stronger performance.